Triamterene is a potassium-sparing diuretic primarily used to treat edema (fluid retention) associated with congestive heart failure, liver cirrhosis, nephrotic syndrome, and certain renal disorders. It is also used as an adjunct to control hypertension, often combined with thiazide diuretics to counteract thiazide-induced potassium loss. By blocking sodium channels in the distal renal tubules, triamterene decreases sodium reabsorption and promotes mild diuresis while conserving potassium. Clinicians may prefer triamterene for patients who are prone to hypokalemia or when maintaining potassium balance is clinically important. While effective for reducing swelling and supporting blood pressure control, triamterene is not typically a first-line monotherapy for severe hypertension.
Dosage depends on the formulation and clinical indication. Typical monotherapy dosing ranges from 100 mg to 300 mg per day, often given as 100 mg twice daily or as directed by a clinician; some regimens start at 50–100 mg once daily with upward titration as needed. When combined with a thiazide diuretic (common fixed-dose products pair triamterene with hydrochlorothiazide), the combination is usually administered once or twice daily at fixed strengths—for example, triamterene 37.5 mg with hydrochlorothiazide 25 mg once daily or twice daily depending on the product and patient needs. Take triamterene with or after meals to reduce stomach upset, and take doses at the same time each day to maintain steady effects. Individual adjustments may be necessary for elderly patients or those with renal impairment; kidney function and electrolytes should be checked before and after initiating or changing doses.
Triamterene can raise serum potassium and so requires careful monitoring in patients at risk of hyperkalemia. Check serum electrolytes and renal function before starting treatment and periodically thereafter, especially within the first week and after dose changes. Use caution in patients with impaired renal function, diabetes, adrenal insufficiency, or those taking other potassium-elevating drugs. Avoid routine use with potassium supplements or salt substitutes that contain potassium unless advised and monitored by a clinician. Triamterene may reduce the effectiveness of loop and thiazide diuretics in some cases, and nonsteroidal anti-inflammatory drugs (NSAIDs) can blunt diuretic response and increase the risk of renal dysfunction. Exercise caution in older adults who are more susceptible to electrolyte disturbances and orthostatic hypotension. Pregnant or breastfeeding patients should discuss risks versus benefits with a clinician; triamterene is typically avoided in pregnancy unless clearly needed.
Contraindications include known hyperkalemia, severe renal impairment or anuria, and hypersensitivity to triamterene or any inactive ingredients in the formulation. Avoid triamterene in patients who are concurrently receiving potassium-sparing agents that would substantially increase potassium levels without close monitoring. Some fixed combination products are contraindicated in patients who cannot tolerate components such as hydrochlorothiazide; always review the specific product label. Use is also contraindicated in acute renal insufficiency and, in many cases, during pregnancy when safer alternatives exist. Always consult the prescribing information for product-specific contraindications.
Common side effects include dizziness, headache, nausea, vomiting, and gastrointestinal upset. Because triamterene is potassium-sparing, hyperkalemia is the most concerning adverse effect and may cause weakness, fatigue, palpitations, or life-threatening cardiac arrhythmias. Other potential effects include lightheadedness, dehydration, headache, and photosensitivity. Rare but serious adverse events can include renal dysfunction, acute kidney injury, and allergic reactions. Skin rash, blood dyscrasias, or abnormal liver function tests have been reported infrequently. If you experience symptoms suggestive of hyperkalemia (muscle weakness, irregular heartbeat) or signs of severe allergic reaction (swelling, difficulty breathing, hives), seek immediate medical attention.
Triamterene has important interactions with drugs that affect potassium homeostasis or renal function. Concomitant use with ACE inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, potassium supplements, or potassium-containing salt substitutes increases the risk of hyperkalemia. Trimethoprim, commonly found in some antibiotics, can raise potassium further when used with triamterene. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce diuretic efficacy and potentiate renal adverse effects. Combining triamterene with other potassium-sparing diuretics (e.g., spironolactone, amiloride) is generally discouraged due to cumulative potassium retention. Lithium clearance can be reduced by diuretics, potentially increasing lithium toxicity; monitor levels closely. Always provide a full medication list to your prescriber, including over-the-counter products and supplements, to assess interaction risk.
Another available option is to review Wellbutrin information online while considering different healthcare needs.If you miss a dose of triamterene, take it as soon as you remember on the same day unless it is almost time for the next scheduled dose. Do not double up to make up a missed dose, as taking two doses at once increases the risk of side effects, including hyperkalemia. If you miss doses repeatedly, consult your clinician to discuss adherence strategies. Maintain routine monitoring of electrolytes and renal function as advised, and contact your healthcare provider if you experience symptoms that might indicate electrolyte imbalance.
Overdose with triamterene can lead to severe hyperkalemia, dehydration, hypotension, and kidney injury. Early signs of dangerous potassium elevation include muscle weakness, paresthesias, palpitations, and cardiac arrhythmias. Management focuses on stabilizing the heart and lowering serum potassium: administer intravenous calcium to stabilize cardiac membranes if indicated, give insulin with dextrose to shift potassium intracellularly, consider nebulized or intravenous beta-agonists, use sodium bicarbonate for acidosis-driven hyperkalemia, and use potassium-binding resins or dialysis when necessary. Supportive care includes fluid resuscitation and monitoring of renal function and electrolytes. Seek emergency care immediately if overdose is suspected.
Store triamterene at room temperature, away from excessive heat and moisture, and keep it in the original container with the lid tightly closed. Protect the medication from direct sunlight. Keep all medications out of reach of children and pets. Do not flush medications down the toilet; follow local guidelines for safe disposal of unused or expired drugs. If you have specific handling instructions from the pharmacy or manufacturer, follow those to maintain potency and safety. Check expiration dates and do not use the medication beyond that date.
In the United States, triamterene is a prescription medication, and safe access requires clinical assessment. Sunshine Pharmacy offers a legal, structured solution for patients seeking triamterene without a traditional in-person prescription by providing an integrated telehealth and pharmacist-reviewed service. Eligible customers complete a medical questionnaire and, where appropriate, a remote clinician review to determine suitability. If deemed appropriate, the pharmacy issues a valid prescription and dispenses authentic medication with clear instructions and monitoring recommendations. This model ensures regulatory compliance, clinician oversight, and safe dispensing while improving access for patients who benefit from remote evaluation. Always ensure you provide an accurate medical history and current medication list during the assessment.
Important safety information: before starting triamterene, inform your healthcare provider of all medications, herbs, and supplements you take, as well as any history of kidney disease, high potassium, heart disease, or diabetes. Monitoring of serum potassium and renal function is essential, especially during the first week of therapy and after dose changes. Avoid potassium supplements, potassium-containing salt substitutes, and other potassium-sparing drugs unless explicitly directed by your prescriber. Do not drive or operate machinery until you know how triamterene affects you, as dizziness or lightheadedness may occur. If pregnant or breastfeeding, discuss risks and alternatives; triamterene is generally avoided in pregnancy unless benefits outweigh risks.
What patients should know: triamterene helps reduce excess fluid and can support lowering blood pressure, but it requires careful monitoring. Take the medication exactly as prescribed—don’t change the dose or stop abruptly without consulting your clinician. Be aware of foods and products high in potassium (bananas, oranges, potatoes, tomatoes, salt substitutes) and talk to your clinician before using them frequently. Report symptoms of high potassium—muscle weakness, unusual tiredness, irregular heartbeat—or signs of dehydration, lightheadedness, or fainting immediately. Maintain scheduled lab tests to monitor electrolytes and kidney function. If you experience severe side effects, seek urgent medical care.
Triamterene is a potassium-sparing diuretic that reduces water and sodium reabsorption in the kidney by blocking epithelial sodium channels (ENaC) in the distal tubule and collecting duct, which helps conserve potassium while promoting urine output.
It is commonly prescribed for edema (fluid retention) associated with heart failure, liver disease, or certain kidney disorders, and sometimes as an adjunct for mild hypertension—often in combination with thiazide diuretics to prevent potassium loss.
Oral triamterene typically begins to increase urine output within a few hours; peak diuretic effect occurs within several hours and duration commonly spans 6–12 hours depending on dose and formulation. Individual response and renal function affect timing.
Common adverse effects include nausea, vomiting, dizziness, headache, rash, and rarely kidney stones. The most clinically important concern is elevated blood potassium (hyperkalemia), which can cause weakness, palpitations, or cardiac arrhythmias.
Major risks include hyperkalemia—especially in patients with renal impairment or when combined with other drugs that raise potassium—renal dysfunction, and rare blood dyscrasias. Seek urgent care for severe weakness, irregular heartbeat, or fainting.
People with significant kidney disease, severe hyperkalemia, anuria, or hypersensitivity to the drug should avoid it. Caution is needed for those on other potassium-elevating agents, pregnant or breastfeeding individuals, and elderly patients; discuss risks with a clinician.
Dosing varies by indication, formulation, and patient factors; it is often given as a single-agent tablet or combined with hydrochlorothiazide. Always follow a prescriber’s directions—do not adjust dose without medical advice. Clinicians tailor dose to renal function and concurrent therapies.
Routine monitoring includes serum potassium and creatinine/renal function soon after initiation and periodically thereafter, blood pressure checks, and assessment for signs of electrolyte imbalance or dehydration.
Triamterene interacts with ACE inhibitors, ARBs, potassium supplements, NSAIDs, certain beta blockers, heparin, and other potassium-sparing agents—combinations can markedly increase hyperkalemia risk. Inform providers of all medications, supplements, and herbal products.
Pregnancy and lactation decisions require individualized assessment. Limited data suggest caution; potential risks to fetus or nursing infant should be weighed against benefits. Consult an obstetrician or pediatrician before use.
Overdose can cause severe hyperkalemia, low blood pressure, dizziness, and kidney impairment. Seek immediate emergency medical care; treatment may include cardiac monitoring, measures to lower potassium, and supportive care per toxicology guidance.
Store at room temperature away from light and moisture, out of reach of children. Dispose of expired or unused medication according to local guidelines or pharmacy take-back programs.
Both preserve potassium, but spironolactone is an aldosterone antagonist that blocks mineralocorticoid receptors, while triamterene blocks ENaC directly. Spironolactone is often more potent for conditions driven by aldosterone (like hyperaldosteronism) and can cause endocrine side effects (gynecomastia); triamterene lacks those hormonal effects but carries hyperkalemia risk too.
Triamterene has minimal endocrine activity, so it generally does not cause gynecomastia, impotence, or menstrual irregularities—side effects sometimes seen with spironolactone—making it preferable when hormonal effects are a concern.
Both block ENaC and are classified as potassium-sparing diuretics; amiloride is often considered more predictable and potent on a milligram-to-milligram basis with a longer duration in some patients. Adverse effect profiles are similar, especially regarding hyperkalemia risk.
Triamterene helps prevent urinary potassium loss by reducing ENaC-mediated exchange, whereas potassium supplements add potassium systemically. Preference depends on the clinical context: triamterene addresses the cause (diuretic-induced wasting), while supplements correct low serum potassium directly; both carry risks and require monitoring.
Combining triamterene with hydrochlorothiazide helps balance thiazide-induced potassium loss while maintaining antihypertensive and diuretic effects. This combination often reduces the need for separate potassium supplements but increases vigilance for hyperkalemia if other risk factors are present.
Loop diuretics are far more potent natriuretics and are preferred for severe edema and heart failure; they cause significant potassium loss and volume depletion. Triamterene is weaker and typically used for mild fluid retention or to offset potassium loss when used with thiazides, not as a substitute in severe cases.
Combining triamterene with ACE inhibitors or ARBs increases hyperkalemia risk more than combining those agents with non–potassium-sparing diuretics. Close potassium and renal monitoring is essential; alternative strategies may be favored if baseline hyperkalemia or renal impairment exists.
Eplerenone is a selective mineralocorticoid receptor antagonist with fewer endocrine side effects than spironolactone; it works differently from triamterene. Choice depends on indication: eplerenone is preferred for heart failure or post-MI indications backed by outcome data, whereas triamterene is chosen mainly for mild fluid retention or to spare potassium.
All potassium-sparing diuretics carry increased hyperkalemia risk with reduced renal function. Dose adjustment and often avoidance are necessary in moderate to severe renal impairment; clinicians may prefer agents with established dosing guidance in renal disease or choose alternatives based on the clinical scenario.
They are not strictly interchangeable because of differences in mechanism, potency, side-effect profiles, and evidence for specific conditions. Substitution should be done by a clinician who can assess indication, comorbidities, and monitoring needs rather than by patients independently.
For long-term aldosterone blockade (e.g., heart failure with reduced ejection fraction or primary aldosteronism), aldosterone antagonists like spironolactone or eplerenone are preferred because they target the pathophysiology and have outcome data; triamterene is not a substitute for mineralocorticoid receptor antagonism in those settings.
